Latest news: CF PharmTech, Inc.

10-07	109,754,801 Ordinary Shares of CF PharmTech, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
10-07	261,025,586 H Shares of CF PharmTech, Inc. are subject to a Lock-Up Agreement Ending on 7-OCT-2026.	CI
09-30	Tranche Update on CF PharmTech, Inc.'s Equity Buyback Plan announced on December 30, 2025.	CI
09-28	CF PharmTech, Inc. commences an Equity Buyback Plan for 30,082,658 shares, representing 7.33% of its issued share capital, under the authorization approved on June 26, 2026.	CI
09-22	CF PharmTech Doses First Subject in Phase I Trial for Inhaled Lung Disease Drug	MT
09-21	Cf Pharmtech, Inc. Completes Enrollment and Dosing of First Healthy Volunteer in Phase I Clinical Trial of Icf004	CI
08-31	CF PharmTech, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-24	CF PharmTech, Inc. Announces Expansion of Indications of ICF001 Following Receipt of Implied Clinical Trial Approvals from the NMPA	CI
07-31	CF PharmTech Eyes HK$295 Million from Share Placement	MT
06-26	Cf Pharmtech, Inc. Announces Board and Supervisor Appointments, Effective June 26, 2026	CI
06-26	CF PharmTech, Inc.'s Equity Buyback announced on December 30, 2025, has expired with 1,397,000 shares, representing 0.38% for HKD 35.9 million.	CI
06-05	CF PharmTech Clears GMP Inspection for Suzhou Inhalation Drug Facility	MT
06-04	CF PharmTech, Inc. Inhalation Formulation Production Base Passes GMP Inspection in PIC/S Member Country	CI

More news

Managers and Directors: CF PharmTech, Inc.

Manager	Title	Age	Since
Wen Qing Liang CEO	Chief Executive Officer	60	01/01/2007
Li Li CTO	Chief Tech/Sci/R&D Officer	67	01/09/2020
Wei Wei DFI	Director of Finance/CFO	47	15/11/2021

Director	Title	Age	Since
Li Li BRD	Director/Board Member	67	01/09/2020
Wen Qing Liang CHM	Chairman	60	01/01/2007
Qi Li BRD	Director/Board Member	67	01/09/2020

More insiders

CF PharmTech, Inc. is a China-based company primarily the research and development, production and sale of respiratory drugs and other related medical products. The Companyâ€™s product portfolio primarily focused on respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. The Company's primary products include CF017, a budesonide suspension for inhalation targeting bronchial asthma, and CF018, an azelastine hydrochloride and fluticasone propionate nasal spray approved for allergic rhinitis. The Company mainly conducts its business in the domestic market.

Employees

625

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	HK$5.980	+1.18%	1,957,000
15/10/26	HK$5.910	-4.29%	2,289,100
14/10/26	HK$6.175	-2.76%	4,992,300
13/10/26	HK$6.350	+3.76%	7,910,300
12/10/26	HK$6.120	+1.07%	2,415,200

Delayed Quote Hong Kong S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - CF PharmTech, Inc.

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Hong Kong S.E. 12:08:16 16/10/2026 +04			5-day change	1st Jan Change
5.980 ^HKD	+1.18%		-1.24%	-82.91%

Market Cap	2.07B 2.43B 310M 275M 255M 232M 438M 29.39B 445M 3.07B 1.2B 15.34B 1.16B 1.14B 48.89B	P/E 2024 *	-	P/E 2025	4,780x
Enterprise Value	1.56B 1.83B 233M 207M 192M 175M 330M 22.14B 335M 2.31B 906M 11.56B 876M 857M 36.84B	EV / Sales 2024 *	-	EV / Sales 2025	28.8x
Free-Float	60.8%	Yield 2024 *	-	Yield 2025	-

1 day	+1.18%
1 week	-1.24%
Current month	-13.77%
1 month	-42.39%
3 months	-63.54%
6 months	-74.60%
Current year	-82.91%

1 week	5.77	6.69
1 month	5.18	11.3
Current year	5.18	39.5
1 year	5.18	39.5
3 years	5.18	48.8
5 years	5.18	48.8
10 years	5.18	48.8

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/09/26	Wen Qing Liang	Other	Chief Executive Officer	25,100	0.0077%
28/09/26	Li Li	Other	Founder	25,100	0.0077%
22/12/25	Wen Qing Liang	Other	Chief Executive Officer	6,500	0.0022%

CF PharmTech, Inc. Stock

Stocks

2652

CNE1000074R9

Pharmaceuticals

Valuation: CF PharmTech, Inc.

Chart: CF PharmTech, Inc.

Latest news: CF PharmTech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: CF PharmTech, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CF PHARMTECH, INC.	+1.18%	-1.24%	-78.96%	-	310M
ELI LILLY AND COMPANY	+0.43%	+6.59%	+53.41%	+103.85%	1,120B
JOHNSON & JOHNSON	+0.90%	-2.25%	+33.02%	+62.23%	616B
ABBVIE INC.	+0.71%	+3.24%	+25.81%	+93.86%	504B
ROCHE HOLDING AG	-0.13%	+5.98%	+32.91%	+50.39%	367B
MERCK & CO., INC.	+0.52%	+0.24%	+73.92%	+40.15%	360B
NOVARTIS AG	-0.95%	+4.70%	+19.51%	+43.00%	288B
ASTRAZENECA PLC	-1.98%	+3.73%	-0.86%	+13.43%	258B
AMGEN INC.	-0.35%	+4.25%	+46.21%	+50.76%	234B
GILEAD SCIENCES, INC.	-0.75%	+3.32%	+32.53%	+97.21%	194B
Average	-0.04%	+3.13%	+23.75%	+61.65%	394.12B
Weighted average by Cap.	+0.13%	+3.83%	+39.17%	+71.44%

	2024	2025
Net sales	608M 713M 90.83M 80.74M 74.83M 68.09M 128M 8.62B 131M 900M 353M 4.5B 341M 334M 14.34B	433M 507M 64.64M 57.46M 53.26M 48.45M 91.43M 6.13B 92.9M 640M 251M 3.2B 243M 237M 10.21B
Net income	21.09M 24.73M 3.15M 2.8M 2.6M 2.36M 4.46M 299M 4.53M 31.21M 12.24M 156M 11.83M 11.58M 498M	2.48M 2.91M 371K 330K 306K 278K 525K 35.25M 534K 3.68M 1.44M 18.39M 1.39M 1.36M 58.64M
Net Debt	-275M -323M -41.1M -36.53M -33.86M -30.81M -58.14M -3.9B -59.07M -407M -160M -2.04B -154M -151M -6.49B	-511M -599M -76.32M -67.84M -62.88M -57.21M -108M -7.24B -110M -756M -296M -3.78B -286M -280M -12.05B